4 top lessons the Theranos scandal can teach us as investors 

The Theranos story presents a timely reminder of some age-old investment wisdom that can help me avoid some basic stock-picking pitfalls.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I, like many of you, will be watching the gripping miniseries, The Dropout. It unpacks one of the most bizarre cases of corporate fraud you will ever see. By a blood-testing start-up called Theranos, no less.

The company managed to dupe many high-profile investors. It shows me that I am never too old to learn an investment lesson.

Putting the Theranos case study into context

So, in 2014 Elizabeth Holmes was a 30-year-old billionaire. She had founded a company valued at $9bn (£6.5bn) for supposedly bringing about a revolution in diagnosing disease.

The only problem? The technology didn’t work.

Soon enough, Holmes was exposed as a fake. In honour of the high-profile debacle, here are five lessons from the Theranos story that continue to serve me well in my investment journey. 

Always evaluate the track record of the management team

Firstly, a big clue is in the title of the miniseries – The Dropout. The fact the CEO of the start-up was a university dropout with no track record in the medical industry is an immediate red flag for me.

The saying goes, “there are no bad companies, only bad managers.” To invest, I must believe beyond doubt that the management team are competent and know what they are doing. Otherwise, I don’t!

Don’t worry about other people

As with many trends in life, herd theory occurs in finance when investors follow the crowd instead of their own analysis. In the case of Theranos, the crowd included bigwigs like Larry Ellison and Henry Kissinger. But, no matter how clever I believe my potential co-investors are, it will never be enough to convince me to invest in a stock. At least not unless I have justified this with my own view.

I never invest in businesses that I do not understand

At one point Theranos claimed to be able to perform all manner of tests, ranging from cholesterol levels to complex genetic analysis. All with just a single pinprick of blood.

Admittedly, I am no geneticist, and haven’t met many. This, in all likelihood, means that I will not understand complex genetic analysis. That is my personal signal to avoid investment.

If I don’t understand a stock, I do not invest in it.

I avoid concentration risk at all costs

Concentration risk occurs when I rely too much on a single investment; for example, a single company’s shares.

So, my prime objective is to avoid an over-reliance on a particular stock or security. My portfolio could be exposed to severe losses if the company goes bust. This turned out to be the reality for many an investor in Theranos.

As such, I counter this by spreading my investment risk by diversifying across sectors, asset classes and regions.

I will never invest in a business I do not understand

In conclusion, investment sage Warren Buffett once said “never invest in a business you cannot understand”. This is the rule I have found to be the most important in my stock-picking journey.

As an investor, independent thought and analysis has served me well.

In the end, I’d rather blame myself for my investment mistake, than someone like Elizabeth Holmes.

Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Down 35% in 2 months! Should I buy NIO stock at $5?

NIO stock has plunged in recent weeks, losing a third of its market value despite surging sales. Is this EV…

Read more »

Two employees sat at desk welcoming customer to a Tesla car showroom
Investing Articles

Could 2026 be the year when Tesla stock implodes?

Tesla's 2025 business performance has been uneven. But Tesla stock has performed well overall and more than doubled since April.…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Could these FTSE 100 losers be among the best stocks to buy in 2026?

In the absence of any disasters, Paul Summers wonders if some of the worst-performing shares in FTSE 100 this year…

Read more »

Midnight is celebrated along the River Thames in London with a spectacular and colourful firework display.
Investing Articles

Up 184% this year, what might this FTSE 100 share do in 2026?

This FTSE 100 share has almost tripled in value since the start of the year. Our writer explains why --…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

You can save £100 a month for 30 years to target a £2,000 a year second income, or…

It’s never too early – or too late – to start working on building a second income. But there’s a…

Read more »

Hydrogen testing at DLR Cologne
Investing Articles

Forget Rolls-Royce shares! 2 FTSE 100 stocks tipped to soar in 2026

Rolls-Royce's share price is expected to slow rapidly after 2025's stunning gains. Here are two top FTSE 100 shares now…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

Brokers think this 83p FTSE 100 stock could soar 40% next year!

Mark Hartley takes a look at the factors driving high expectations for one major FTSE 100 retail stock – is…

Read more »

Investing Articles

I asked ChatGPT for the best FTSE 100 shares to consider for 2026, and it said…

Whatever an individual investor's favourite strategy, I reckon there's something for everyone among the shares in the FTSE 100.

Read more »